These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27480549)

  • 1. [The considerations on hot topics of cholesterol-lowering therapies].
    Guo YF
    Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):589-91. PubMed ID: 27480549
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk reduction: the future of cholesterol lowering drugs.
    Bou Malham S; Goldberg AC
    Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined use of cholesterol-lowering drugs and cholesterol-lowering bread spreads: health behavior data from Finland.
    de Jong N; Simojoki M; Laatikainen T; Tapanainen H; Valsta L; Lahti-Koski M; Uutela A; Vartiainen E
    Prev Med; 2004 Nov; 39(5):849-55. PubMed ID: 15475015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol-lowering drugs and antidepressants--a study of prescription symmetry.
    Lindberg G; Hallas J
    Pharmacoepidemiol Drug Saf; 1998 Nov; 7(6):399-402. PubMed ID: 15073969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol-lowering nutraceuticals and functional foods.
    Chen ZY; Jiao R; Ma KY
    J Agric Food Chem; 2008 Oct; 56(19):8761-73. PubMed ID: 18778072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pravastatin, a new cholesterol synthesis inhibitor for lowering increased serum cholesterol].
    Hoppichler F; Lechleitner M; Patsch JR
    Z Gesamte Inn Med; 1992 Nov; 47(11):523-7. PubMed ID: 1462678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets and emerging therapies for reducing LDL cholesterol.
    Lilly SM; Rader DJ
    Curr Opin Lipidol; 2007 Dec; 18(6):650-5. PubMed ID: 17993811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [All mortality by cause of death. The challenge of coronary prevention].
    Fernández-Cruz A
    Rev Esp Cardiol; 1998; 51 Suppl 6():23-9. PubMed ID: 10050141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy.
    Hoenig MR; Rolfe BE; Campbell JH
    Atherosclerosis; 2006 Feb; 184(2):247-54. PubMed ID: 16216250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT.
    De Caterina R; Salvatore T; Marchioli R
    Atherosclerosis; 2016 May; 248():216-8. PubMed ID: 27035113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of lowering cholesterol on mortality].
    Schmidt JG
    Schweiz Med Wochenschr; 1993 Nov; 123(45):2150-5. PubMed ID: 8266036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.